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The complement system is an essential compo-
nent of the innate immune response against mi-
croorganisms. It consists of a network of soluble 
and cell surface proteins that recognize and 
target pathogens. Complement activation con-
trols viral infections through multiple mech-
anisms, including enhanced B and T cell priming, 
release of anaphylatoxins (C3a, C4a, and C5a) 
that recruit leukocytes to the site of infection, 
production of opsonins (C1q, mannose bind-
ing lectin [MBL], C4b, and C3b) that bind   
viral particles, and formation of C5b-9 mem-
brane attack complexes that lyse virions and/or 
infected cells (for review see Avirutnan et al., 
2008). In response, viruses have evolved strate-
gies to limit recognition by and activation of 
the complement cascade, including expression 
of surface proteins that bind the Fc domain of 
antibodies to prevent C1q-dependent comple-
ment activation, secretion of soluble viral pro-
teins that mimic or recruit host complement 
regulators, direct incorporation of host com-
plement control proteins on the virion, and 
up-regulation of complement regulatory proteins 
on the surface of infected cells (for review see 
Lambris et al., 2008).
Dengue virus (DENV) is a single-stranded 
positive sense enveloped RNA Flavivirus that 
is genetically related to several other major   
human pathogens, including West Nile virus 
(WNV) and yellow fever virus (YFV). DENV 
is a mosquito-transmitted pathogen that causes 
clinical syndromes in humans ranging from an 
acute self-limited febrile illness (dengue fever 
[DF]) to a severe and life-threatening vascular 
leakage and bleeding diathesis (dengue hemor-
rhagic fever/dengue shock syndrome [DHF/
DSS]). Globally, DENV causes an estimated 50 
million infections annually, resulting in 500,000 
hospitalizations and 22,000 deaths (Morens 
and Fauci, 2008). Four serotypes of DENV   
circulate, and DHF/DSS is commonly associ-
ated with a secondary infection by a different   
serotype. Although antibody (Ab)-dependent 
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The complement system plays an essential protective role in the initial defense against 
many microorganisms. Flavivirus NS1 is a secreted nonstructural glycoprotein that accumu-
lates in blood, is displayed on the surface of infected cells, and has been hypothesized to 
have immune evasion functions. Herein, we demonstrate that dengue virus (DENV), West 
Nile virus (WNV), and yellow fever virus (YFV) NS1 attenuate classical and lectin pathway 
activation by directly interacting with C4. Binding of NS1 to C4 reduced C4b deposition 
and C3 convertase (C4b2a) activity. Although NS1 bound C4b, it lacked intrinsic cofactor 
activity to degrade C4b, and did not block C3 convertase formation or accelerate decay of 
the C3 and C5 convertases. Instead, NS1 enhanced C4 cleavage by recruiting and activating 
the complement-specific protease C1s. By binding C1s and C4 in a complex, NS1 promotes 
efficient degradation of C4 to C4b. Through this mechanism, NS1 protects DENV from 
complement-dependent neutralization in solution. These studies define a novel immune 
evasion mechanism for restricting complement control of microbial infection.
© 2010 Avirutnan et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons.
org/licenses/by-nc-sa/3.0/).
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enhancement of DENV infection in Fc receptor-bearing 
cells has been proposed to initiate pathogenesis (Halstead, 
1988),  the  mechanism  for  how  vascular  leakage  occurs   
remains uncertain. Cytopathic effects of virulent strains of 
DENV, a proinflammatory cytokine storm secondary to exu-
berant activation of poorly lytic cross-reactive T cells, and 
excessive complement activation have been suggested to 
contribute to the vascular leakage syndrome (for review see 
Clyde et al., 2006).
The 11-kb Flavivirus RNA genome encodes a polypro-
tein that is cleaved by viral and host proteases to generate 
three structural and seven nonstructural proteins. Flavivirus 
NS1 is a 48-kD nonstructural glycoprotein that is absent   
from the virion. NS1 is an essential gene as it is a required 
cofactor for the NS5 polymerase during viral RNA repli-
cation (Mackenzie et al., 1996; Lindenbach and Rice, 1997; 
Khromykh et al., 1999). In infected mammalian cells, NS1 is 
synthesized as a soluble monomer, dimerizes after posttransla-
tional modification in the lumen of the endoplasmic reticulum, 
and is transported to the cell surface and accumulates extracellu-
larly as higher order oligomers, including a hexamer (Flamand 
et al., 1999). Soluble NS1 also binds back to the plasma mem-
brane of cells through interactions with specific sulfated   
glycosaminoglycans (Avirutnan et al., 2007). DENV NS1 has 
been implicated in the pathogenesis of DHF/DSS, although 
the mechanism remains uncertain. High levels of NS1 are   
detected in the serum of DENV-infected patients and corre-
late with severe disease (Libraty et al., 2002; Avirutnan et al., 
2006). NS1 has been proposed to facilitate immune complex 
formation (Avirutnan et al., 2006); elicit autoantibodies that 
react with platelet and extracellular matrix proteins (Falconar, 
1997) or damage endothelial cells via Ab-dependent, com-
plement-mediated cytolysis (Lin et al., 2003); and directly   
enhance infection (Alcon-LePoder et al., 2005). Recently, 
WNV NS1 was shown to attenuate the alternative pathway of 
complement activation by binding the complement regula-
tory protein factor H (Chung et al., 2006a).
Here, we describe a novel immune evasion function of 
soluble Flavivirus NS1: specific inhibition of the classical and 
lectin pathway of complement activation through a direct   
interaction with C4 and C1s. DENV, WNV, and YFV NS1 
all limit C4b deposition and classical and lectin pathway C3 
convertase activity by enhancing cleavage of C4 through the 
recruitment of the complement-specific protease C1s.
RESULTS
DENV NS1 directly binds to C4/C4b and inhibits classical 
pathway (CP) activation
Based on a previous study with WNV NS1 (Chung et al., 
2006a), we hypothesized that DENV NS1 might target the 
human complement system to attenuate the host immune   
response. An ELISA was used to screen for interactions be-
tween DENV NS1 and human complement proteins. Micro-
titer plates were adsorbed with purified human complement 
proteins (Fig. 1 and not depicted). Serum-free supernatants 
from baby hamster kidney (BHK) cells that stably propagate a 
Figure 1.  Direct binding of DENV NS1 to C4 and C4b. (A) ELISA. 
Microtiter plates were coated with BSA, C4, or C4b (5 µg/ml). After incu-
bation with serum-free supernatants from BHK-DENV2-Rep cells or con-
trol BHK cells, bound DENV NS1 was detected using DENV NS1–specific 
mAbs. Data are the mean ± SD for three independent experiments. Aster-
isks denote NS1 binding that is statistically different from binding to 
background (**, P < 0.005; ***, P < 0.0005). (B–E) Reciprocal co-immuno-
precipitation. Serum-free supernatants from BHK-DENV2-Rep or control 
BHK cells were incubated with purified C4 (B and D) or C4b (C and E;  
20 µg/ml) and Western blots were performed after immunoprecipitation 
with anti-DENV NS1 mAb (2G6)–Sepharose (B and C) or anti–human  
C4–Sepharose (D and E). Immunoprecipitated material was probed with  
a goat polyclonal anti–human C4 Ab or DENV NS1–specific mAb (1F11), 
respectively. Subunits and cleavage fragments of C4 and C4b are labeled 
to the right of the gel; a 93-kD  chain of C4; 84-kD ’ chain of C4b; and 
78-kD  chain of C4 and C4b. Notably, in the starting material of this C4 
preparation, 20–30% was C4b. Western blot results are representative of  
two or three independent experiments.
DENV-2 subgenomic replicon (BHK-DENV2-Rep cells) 
and secrete high levels (up to 4 µg/ml) of NS1 (Avirutnan   
et al., 2007) and from control BHK cells were added to   
complement  protein-coated  wells.  Bound  DENV  NS1 
was detected using specific mAbs (Puttikhunt et al., 2003; 
Avirutnan et al., 2007). A strong interaction between DENV 
NS1 and C4 or C4b was identified (Fig. 1 A). Reciprocal   JEM VOL. 207, April 12, 2010 
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co-immunoprecipitation experiments confirmed the NS1 and 
C4/C4b interaction (Fig. 1, B–E). However, the interaction 
of C4 or C4b and DENV NS1 is noncovalent, as the two 
proteins independently migrate at their expected sizes by elec-
trophoresis and Western blot.
The functional significance of the NS1–C4 interaction 
was demonstrated in sheep erythrocyte (E) hemolysis assays 
in which the CP was activated by rabbit anti–sheep poly-
clonal Abs (Fig. 2). Each purified complement component 
Figure 2.  DENV NS1 inhibits C4 to prevent CP dependent hemoly-
sis. (A and B) Human C4 was incubated in the presence or absence of 
DENV NS1 and then added to sensitized EA bearing C1 (EAC1). After three 
washes, the EAC14b cells were incubated with purified C2, washed, and 
incubated with GPS treated with EDTA (A) or purified human components 
(B; C3-C9) at 37°C for 30 min. After centrifugation, the supernatant was 
analyzed by spectrophotometry at 414 nm. (C) Single-step hemolysis  
assay. EA were incubated with an 80-fold dilution of C4-deficient GPS that 
was supplemented with human C4, with or without preincubation with 
DENV NS1. The data represent the mean ± SD for three independent ex-
periments. Asterisks denote hemolysis conditions that are statistically 
different from untreated cells (*, P < 0.05; **, P < 0.005; ***, P < 0.0005).
was sequentially added to Ab-sensitized E (EA) in the pres-
ence or absence of DENV NS1. Preincubation of purified 
DENV NS1 with human C4, but not with C1, C2, or C3 
(unpublished data) interfered with hemolysis in three differ-
ent assays in which the complement proteins were limiting: 
(a) addition of purified components C1, C4, and C2 to EA 
(EAC14b2a) followed by an incubation with a 20-fold dilu-
tion of guinea pig serum (GPS) as the source of C3 and   
terminal  complement  components  (C5-C9)  in  an  EDTA 
containing buffer (GPS-EDTA; Fig. 2 A); (b) sequential ad-
dition of purified human C1-C9 to EA, in which purified 
C3-C9 was added to EAC14b2a instead of GPS-EDTA (Fig. 
2 B); and (c) a single-step hemolysis assay in which EA were 
incubated with an 80-fold dilution of C4-deficient GPS   
supplemented with human C4 that had been preincubated in 
the presence or absence of DENV NS1 (Fig. 2 C). The speci-
ficity of DENV NS1 for inhibiting hemolytic activity was 
confirmed in preclearance experiments (Fig. S1 A) as follows: 
preincubation of DENV NS1 with anti-NS1 (2G6)– but   
not anti-E (4G2)–Sepharose abolished the inhibitory effect   
(Fig. S1 B). Notably, the amount and inhibitory activity of 
DENV NS1 after the preclearing step with 4G2–Sepharose 
was similar to that observed with a 1:2 dilution of starting 
material. The concentrations of NS1 used in these studies 
have been observed in plasma and pleural fluid of human   
patients infected with severe DENV infection (Alcon et al., 
2002; Libraty et al., 2002; Avirutnan et al., 2006). Collec-
tively, these functional experiments suggest that DENV NS1 
specifically inhibits CP-induced lysis of targets via an interac-
tion with C4.
DENV NS1 reduces CP C4b deposition
Next, we confirmed the complement inhibitory activity of 
DENV NS1 by measuring C4b and C3b deposition on the 
surface of EA. Pre-incubation of DENV NS1 with human 
C4 reduced C4b and C3b deposition in a dose-dependent 
manner (Fig. 3) and prevented cell lysis (Fig. 2, A–C). As   
expected, equivalent amounts of the control protein (BSA) 
did not interfere with C4b and C3b deposition (Fig. 3). To 
test if soluble NS1 also attenuates complement deposition   
on the cell surface of nucleated mammalian cells, we used an   
established Chinese hamster ovary (CHO) cell model sys-
tem of complement activation (Barilla-LaBarca et al., 2002;   
Liszewski et al., 2008). Cells were sensitized with a polyclonal 
Ab against CHO cell surface antigens and the magnitude of 
C4b and C3b deposition was monitored by flow cytometry. 
Purified human CP complement components (C1, C4, C2, 
and C3) were preincubated with DENV NS1 in solution and 
subsequently added to Ab-sensitized CHO cells. As expected, 
DENV NS1 but not BSA decreased the amount of C4b and 
C3b deposited on the CHO cell surface (Fig. 3, E and F).
Based on the above experiments, DENV NS1 down-
modulated CP-induced lysis of EA via a direct interaction 
with C4 through one of several possible mechanisms: (a) inhibit-
ing C4 cleavage by C1; (b) preventing C4b attachment to the 
target cell surface; (c) preventing the CP convertase assembly;   796 Flavivirus NS1 inhibits C4 function | Avirutnan et al.
C3 and C5 convertases (point c and d in the previous section; 
Lambris et al., 2008). To test whether DENV NS1 had   
this activity, we again used a hemolysis assay. In contrast to a   
soluble complement regulator, C4 binding protein (C4BP), 
which interferes with CP convertase assembly (Gigli et al., 
1979), incubation of DENV NS1 with C1- and C4-treated 
(d) inhibiting CP convertase formation and stability; or (e) pro-
moting C4 degradation in solution.
DENV NS1 lacks the ability to regulate the CP convertases
A common mechanism for pathogens to evade human com-
plement is to inactivate the central proteolytic enzymes, the 
Figure 3.  DENV NS1 reduces C4b and C3b deposition on the surface of cells. Human C4 was incubated with serially diluted purified DENV NS1 or 
BSA (12.5, 25, or 50 µg/ml) for 1 h before adding EAC1. After a 15-min incubation at 30°C, EAC14b were sequentially incubated with C2 and C3. After 
three washes, the deposition of C4b (A and C) and C3b (B and D) was determined by incubating EAC14b2a3b with anti-C4c or anti-C3c mAb, and analyzed 
by flow cytometry. Examples of histogram profiles in which DENV NS1, but not BSA, blocks C4b (A) and C3b (B) deposition are depicted. In C and D, data 
are expressed as the specific mean fluorescence intensity (MFI) of staining. The error bars indicate SD corresponding to three independent experiments. 
Asterisks denote C4b or C3b deposition that is statistically different from untreated cells (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). (E and F) Soluble DENV 
NS1 restricts complement deposition on the surface of nucleated cells. CHO cells were sensitized with rabbit anti-CHO surface antigen IgG before incuba-
tion with the mixture of DENV NS1 or BSA (25 µg/ml) and purified human CP complement components C1, C4, C2, and C3, followed by immunostaining 
with murine mAb to human C4d (E) and C3d (F) and analyzed by flow cytometry. EDTA (20 mM) was added to inhibit complement activation for negative 
controls. Examples of histogram profiles from three independent experiments in which DENV NS1, but not BSA, restricted C4b (E) and C3b (F) deposition 
are shown.JEM VOL. 207, April 12, 2010 
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protease activity of factor I for C4b; thus, NS1 lacks intrinsic 
cofactor activity for factor I (Fig. S3).
WNV NS1 also inhibits CP activation via a direct  
interaction with C4
We extended our study to test whether other Flavivirus NS1 
proteins retained this complement inhibitory function. Nota-
bly, WNV and YFV NS1 efficiently bound human C4 and 
C4b (Fig. 4 A), but only WNV NS1 inhibited CP activation 
to a similar extent compared with DENV NS1 (Fig. 4 B). 
Inhibition of CP activation and complement-dependent he-
molysis by DENV and WNV NS1 was observed with C4 from 
guinea pig (Fig. 4 C) or human serum (Fig. 4 D).
DENV and WNV NS1 promote cleavage  
of hemolytically active C4
To determine the mechanism for how NS1 inhibits CP- 
mediated complement activation, we assessed the efficiency 
of C4 cleavage by C1s in the fluid phase in the presence and 
absence of NS1. The ratio of the  and  chain of C4 and 
C4b was analyzed by Western blot. If NS1 acted by inhibit-
ing C4 cleavage by C1s, we would expect greater amounts of 
EA (EAC14b) before adding C2 did not inhibit hemolysis 
(Figs. S1 and S2 A). The same result was obtained if CP C3 
(C4b2a) or C5 (C4b2a3b) convertase was used; thus, incu-
bation with DENV NS1 did not alter lytic activity whereas 
addition of the human regulators soluble complement re-
ceptor 1 (sCR1) and C4BP readily dissociated the conver-
tases and inhibited the CP-induced hemolysis (Fig. S2,   
B and C). Therefore, although DENV NS1 binds C4b,   
it does not prevent convertase assembly or possess decay-
  accelerating activity.
DENV NS1 lacks cofactor activity for factor  
I to degrade C4b
Experiments were performed in the fluid phase to test 
whether NS1-modulated cofactor activity by augmenting the 
ability of factor I to degrade C4b in solution. Purified DENV 
NS1 was incubated with C4b, followed by sequential addi-
tion of factor I, with or without a known cofactor. Subse-
quently, C4b cleavage products were identified by Western 
blot using anti–C4d-specific mAbs. In contrast to the estab-
lished cofactors C4BP, membrane cofactor protein (MCP), 
and CR1, addition of DENV NS1 did not enhance the   
Figure 4.  DENV and WNV NS1 inhibit CP activation via a direct interaction with C4. (A) DENV, WNV, and YFV NS1 interact with human C4/C4b. 
Microtiter plates were coated with BSA, C4, or C4b (5 µg/ml). After incubation with purified DENV, WNV, or YFV NS1 (5 µg/ml), bound NS1 was detected 
using DENV, WNV, or YFV NS1-specific mAbs. (B) EA were incubated with a 160-fold dilution of C4-deficient GPS that was supplemented with purified 
human C4 (63 ng/ml), with or without preincubation with DENV, WNV, or YFV NS1 or BSA (12.5–50 µg/ml). (C and D) DENV and WNV NS1 inhibit  
C4-mediated CP in guinea pig and human sera. EA were incubated with a 160-fold dilution of C4-deficient GPS that was supplemented with the  
indicated dilutions of fresh guinea pig (C) or human serum (D), with or without preincubation with DENV or WNV NS1 (50 µg/ml). Data are the mean ± 
SD for three independent experiments. Asterisks denote NS1 binding that is statistically different from binding to background (A) or hemolysis  
conditions which are statistically different from untreated cells (B–D; *, P < 0.05; **, P < 0.005; ***, P < 0.0005).798 Flavivirus NS1 inhibits C4 function | Avirutnan et al.
absence of C1s when C4 was incubated with WNV NS1 but 
not with control proteins, BSA or lysozyme (Fig. 5 A); thus, 
NS1-dependent C4 cleavage in the fluid phase was analogous 
to that observed with C1s (Fig. 5 B). Cleavage of C4 in the 
presence of NS1 was also confirmed by detection of the small 
fragment C4a (Fig. 5 C). Nonetheless, C4 cleavage in the 
presence of NS1 was specific; incubation of purified C3 with 
NS1 did not result in degradation of the C3  chain, even   
after prolonged incubation at 37°C (Fig. S4).
Because  NS1  sequence  does  not  encode  any  known   
protease motifs, one possibility was that the C4 but not C3 
cleavage activity was caused by C4-specific proteases that   
copurified with NS1. To evaluate this, we assayed whether 
protease inhibitors could block NS1-dependent cleavage of 
C4. Among the protease inhibitors tested including phenyl-
methylsulfonylfluoride and commercial protease inhibitor 
cocktails (data not shown), the NS1-dependent C4b   
chain accumulation was most efficiently inhibited by the   
plasma serine protease inhibitor, C1 inhibitor (C1-INH;   
Fig. 5 C). Correspondingly, C1-INH also abrogated C4 
inhibitory activity of WNV and DENV NS1 in hemolysis 
assays (Fig. 5 D).
C1s/C1s proenzyme copurifies with WNV and DENV NS1
Because  the  complement  protease  C1s  is  blocked  by   
C1-INH (Ziccardi, 1982) and is synthesized and secreted by 
a variety of cell types (Thielens and Arlaud, 2000), we evalu-
ated whether hamster (from BHK cells) C1s copurified with 
NS1. Initially, a two-step purification was performed to gen-
erate highly purified preparations of NS1 (Avirutnan et al., 
2007). The elution profile of affinity-purified WNV NS1 
(first column) followed by ion-exchange (second) column 
displays a heterogeneous profile (Fig. 6 A), which is likely 
caused by the presence of oligomers of soluble NS1 (Flamand 
et al., 1999; Fig. S5). The heterogeneity in size was con-
firmed by size exclusion chromatography (Fig. 6 F and Fig. S6). 
After purification, each fraction of NS1 was tested for C4   
inhibitory activity in the hemolysis assay, as well as the pres-
ence of hamster C1s by Western blot with a cross-reactive 
anti–human  C1s  polyclonal  Ab.  After  separation  by  ion- 
exchange chromatography, all fractions of WNV NS1 had 
C4 inhibitory activity, with the exception of the main peak 
fractions (B8-B10; Fig. 6 B). In our functional experiments 
(Figs. 2–5), high concentrations of NS1 (20–50 µg/ml) were 
required to inhibit hemolysis. However, when the fraction 
with peak activity (fraction C1; Fig. 6, A and B) was serially 
diluted and subjected to the C4 hemolysis assay, the specific 
C4 inhibitory activity was observed at a much lower con-
centration of NS1 (1.75 µg/ml; Fig. 6 C). Hamster C1s was   
detected in most of the fractions of purified WNV NS1 that 
had C4 inhibitory activity, but not in the NS1 fractions that 
lacked activity (Fig. 6 D). Correspondingly, the fractions of 
WNV NS1 after size exclusion chromatography that exhib-
ited inhibitory activity in the C4 hemolysis assay (Fig. 6,   
F and G) also had detectable levels of C1s (Fig. 6 H). Although 
similar results were observed with DENV NS1, hamster C1s 
C4- compared with C4b- chain. Instead, preincubation 
of DENV NS1 with C4, before addition of C1s, increased 
the generation of the C4b- chain (Fig. 5 A). This result was 
initially surprising to us because, if NS1 promoted C4b- 
chain accumulation on the erythrocyte cell surface, it should 
have enhanced hemolysis. However, a loss of C4- chain 
and accumulation of C4b    chain was also observed in the 
Figure 5.  Purified DENV NS1 and WNV NS1 promote C4 cleavage. 
(A and B) Western blot analysis. (A) Purified DENV NS1, WNV NS1, BSA, or 
lysozyme (50 µg/ml) was preincubated with C4 (6.25 µg/ml) for 1 h on ice. 
Subsequently, the NS1-C4, BSA-C4, and lysozyme-C4 solutions were incu-
bated at 30°C for 15 min. (B) Purified C4 was incubated with C1s (12 µg/ml)  
for 1 h at 30°C. Subunits and cleavage fragments of C4 and C4b are  
labeled to the right of the gel; 93 kD  chain of C4; 84 kD ’ chain of C4b. 
(C and D) Inhibition of C4 cleavage in the presence of NS1 by C1 inhibitor 
(C1-INH). (C) C4a ELISA. C4 was incubated with purified DENV NS1 or 
lysozyme (30 µg/ml) in the presence or absence of C1-INH (1.4 µg/ml) on 
ice for 1 h. (D) Single-step hemolysis assay. EA were incubated with a 
160-fold dilution of C4-deficient GPS supplemented with human C4  
(0.1 µg/ml) that was preincubated with DENV or WNV NS1 (30 µg/ml) in 
the presence or absence of C1-INH (40 µg/ml). In some experiments, C1 
inhibitor (C1-INH; 40 µg/ml) was added to before the incubation with  
EA- and C4-deficient GPS. Data are the mean ± SD for four independent  
experiments. Asterisks denote C4a liberation (C) as measured by ELISA 
that is statistically different (**, P < 0.005) or hemolysis conditions (D) 
that are statistically different from untreated cells (***, P < 0.0005).JEM VOL. 207, April 12, 2010 
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three distinct bands corresponding to the  and  chains of 
activated C1s and proC1s. In contrast, only a single band of 
proC1s was observed in a concentrated (100-fold) serum-free 
culture supernatant from uninfected BHK cells (Fig. 6 E). 
Autocatalytic activation of proC1s independent of its activa-
tor C1r has been previously shown (Morgan and Nair, 1975). 
ProC1s may have become auto-activated during the purifi-
cation process or alternatively, binding of NS1 to proC1s   
induced autocatalysis.
was not detected in purified fractions of YFV NS1 (not   
depicted); consistent with this, YFV NS1 bound C4, but did 
not inhibit in the hemolysis assay (Fig. 4 B).
C1s is synthesized as a single 80-kD chain proenzyme 
(proC1s) and activated after cleavage of a single peptide bond 
between amino acids R437 and I438, yielding a disulfide-
linked 52-kD  chain and 28- kD  chain (Thielens and   
Arlaud, 2000). Reducing SDS-PAGE and Western blot anal-
ysis of the hamster C1s that copurified with NS1 revealed 
Figure 6.  C1s/proC1s copurifies with NS1. (A) Two-step purification of WNV NS1. Immunoaffinity-purified WNV NS1 was passed over an ion-
  exchange column, and NS1 was eluted with a linear NaCl gradient (diagonal line). Silver stain and Western blot of each fraction were performed (Fig. S5 and 
not depicted). All fractions were tested for C4 inhibitory activity in a single-step hemolysis assay (B). C4 (0.1 µg/ml) was preincubated with an individual 
concentrated fraction (25 µl) before the addition of EA- and C4-deficient GPS (1:160). Fractions with C4 inhibitory activity are bracketed (A and B).  
(C) WNV NS1 fraction #C1 from ion exchange chromatography was twofold serially diluted and subjected to a single-step C4 hemolysis assay.  
(D and E) Western blot analysis for C1s/proC1s from ion exchange fractions shown in A. (D) Nonreduced SDS-PAGE. Lane 1, 100-fold concentrated serum-
free culture supernatants (SFM) of BHK cells; lanes 2–7, 10-fold concentrated purified WNV NS1 fractions after ion-exchange chromatography. The pro-
teins were separated on a 4–12% gradient nonreduced SDS-PAGE, transferred, and probed with a goat anti–human C1s serum. The anti–human C1s Ab 
cross-reacts with hamster C1s. (E) SDS-PAGE, reducing conditions. Lane 1, 100-fold concentrated SFM of BHK cells; lanes 2 and 3, purified human C1s 
(huC1s) and human proC1s (huProC1s; 10 ng); lanes 4–8, 10-fold concentrated purified WNV NS1 fractions after ion-exchange chromatography. (F) Size 
exclusion chromatography profile of affinity-purified WNV NS1. Molecular sizes of indicated fractions were calculated from a set of protein standards 
loaded on the same column. (G) Size exclusion chromatography fractions were collected, concentrated 10-fold, and subjected to a single-step hemolysis 
assay as described in B, as well as a nonreduced SDS-PAGE and Western blot with anti–human C1s Ab (H). Brackets denote the fractions that inhibit  
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also observed (Fig. 7, C and F, and Fig. S6 B), suggesting   
an avid interaction. Based on the column migration pat-
terns, we postulated a direct interaction between NS1 and 
C1s/proC1s. Binding assays confirmed that DENV, WNV, 
and YFV NS1 directly interacted with human C1s and 
proC1s (Fig. 7, G and H).
Although all of our experiments suggested that NS1 could 
interact with both C4 and C1s to limit complement activa-
tion, an underlying concern was that the interaction with 
C1s was still nonspecific. We reasoned that a nonspecific   
interaction should not affect the inherent enzymatic activity 
of C1s. However, if NS1 enhanced the C4 cleavage activity 
of C1s, it would strongly support the concept of a specific 
functional interaction. We evaluated this hypothesis using a 
modified  hemolysis  assay.  Purified  NS1  was  preincubated 
with human C1s or proC1s before the addition of human 
C4; subsequently, C4-deficient GPS was added to sensitized 
Flavivirus NS1 directly binds C1s/C1s proenzyme  
and enhances cleavage of C4
As our data suggested a separate biochemical interaction be-
tween NS1 and C1s, experiments were performed to test if 
NS1  physically  interacted  with  C1s  and  C1s  proenzyme.   
Purified human proC1s, WNV NS1, or mixtures of both 
were  separated  by  size  exclusion  chromatography.  When 
proC1s was run alone, Western blot analysis showed that it 
was present exclusively in fractions B9 and B10 (Fig. 7 A). 
When the same amount of proC1s was preincubated with 
WNV NS1, it distributed more broadly over the fractions 
that contain WNV NS1 (Fig. 7, B and C). Importantly, the 
distribution of a Fab fragment of similar size but irrelevant 
specificity did not change when mixed with WNV NS1   
(Fig. 7, D and E). Additionally, a change in the distribu-
tion pattern of size exclusion chromatography fractions that 
contained WNV NS1 after binding to human proC1s was 
Figure 7.  Flavivirus NS1 directly binds to C1s/proC1s. (A–F) Size-exclusion chromatography. Purified huProC1s (A) or Fab fragment of murine mAb 
to WNV E (E9-Fab; D) or the mixture of huProC1s + WNV NS1 (B and C) or E9-Fab + WNV NS1 (E and F) were fractionated by size exclusion chromatogra-
phy. Fractions were concentrated 10-fold, separated on SDS-PAGE under reducing (A–C) or nonreducing (D–F) conditions and immunoblotted with goat 
antiserum to huC1s (A and B), goat anti–mouse IgG (D and E), or mouse anti-WNV NS1 (C and F). Subunits of C1s are labeled to the right of the gel; an 
85-kD subunit of huProC1s or huC1s; a 52-kD  chain of huC1s; and a 23-kD  chain of huC1s. Of note, a subset of proC1s was activated during the 
fractionation to become C1s (A and B). Results are representative of two independent experiments. (G and H) ELISA. Microtiter plates were coated with 
purified BSA and huC1s (G) or BSA and huProC1s (H). After incubation with affinity-purified DENV, WNV, or YFV NS1, bound NS1 was detected using 
DENV-, WNV-, or YFV NS1–specific mAbs, respectively. Specific binding was calculated by subtracting the OD in antigen-coated wells from the OD. in 
BSA-coated wells. Data are presented as the mean ± SD for three independent experiments.JEM VOL. 207, April 12, 2010 
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sheep EA. Higher concentrations of C4 were used in this   
assay compared with the previous hemolysis experiments to 
overcome the inherent C4 cleavage activity of hamster C1s/
proC1s that copurified with WNV and DENV NS1. Nota-
bly,  WNV  and  DENV  NS1,  but  not  BSA  or  lysozyme,   
enhanced the activity of C1s and proC1s to cleave C4 as   
observed by decreased hemolysis (Fig. 8, A and B). Most im-
portantly, although purified YFV NS1 did not associate sig-
nificantly with hamster C1s/proC1s to promote degradation 
of C4 by itself (Fig. 4 B), it readily bound human C1s/proC1s 
(Fig. 7, G and H), which then facilitated cleavage of C4 (Fig. 8, 
A and B) in a manner similar to WNV and DENV NS1.   
Acceleration of C4 degradation in solution by human proC1s 
in the presence of YFV NS1 was confirmed in kinetic ex-
periments (Fig. 8 C). This activity was specific to NS1, as 
lysozyme or BSA did not alter the kinetics of C4 cleavage 
by proC1s (Fig. 8 C and not depicted).
NS1 protects Flaviviruses from complement attack
Complement can directly neutralize Flavivirus virions and 
infectivity (Mehlhop et al., 2005) in vitro and has a protective 
role in restricting WNV infection in mice. Because Flavivirus 
NS1 antagonizes C4 and subsequent C3 deposition, we hypoth-
esized that soluble NS1 that accumulates to high amounts   
(up to 50 µg/ml) in serum (Alcon et al., 2002) could protect 
DENV from direct complement-mediated neutralization. As 
expected, DENV was efficiently neutralized by naive wild 
type GPS (Fig. 9 A). In contrast, C4-deficient GPS or heat-
inactivated wild-type serum failed to diminish DENV infec-
tivity,  confirming  a  complement-dependent  neutralization 
mechanism (Fig. 9, A and B). Addition of purified human C4 
to guinea pig C4-deficient serum restored the ability to neu-
tralize DENV infection in a dose-dependent manner (Fig. 9 B). 
Importantly, the addition of soluble DENV NS1 (Fig. 9 B) or 
WNV NS1 (not depicted), but not BSA, rescued infectivity. 
This antagonistic effect of NS1 was C4-dependent, as addi-
tion of higher concentrations of human C4 overcame the   
inhibition of GPS neutralization by NS1. Although one study 
suggested that pretreatment of cells with soluble DENV NS1 
before infection of hepatoma cells improves virus yield two-
fold (Alcon-LePoder et al., 2005), we did not observe this 
phenomenon; when NS1 was added alone or mixed with 
heat-inactivated serum, no changes in infectivity were ob-
served (Fig. 9 B and not depicted). Collectively, these studies 
demonstrate that soluble NS1 can antagonize C4 function, 
which affects viral infection.
DISCUSSION
Viruses have evolved strategies to avoid recognition and de-
struction by the complement system (for review see Lambris 
et al., 2008). WNV NS1 has previously been shown to atten-
uate alternative pathway activation by recruiting complement 
regulator factor H to facilitate C3b inactivation by factor I 
(Chung et al., 2006a). Herein, we define a novel mechanism 
in which NS1 restricts classical/lectin pathway activation by 
targeting C4. Binding of soluble NS1 to proC1s/C1s and C4 
Figure 8.  Flavivirus NS1 enhances ability of C1s and proC1s to 
cleave C4. Purified WNV, DENV, or YFV NS1 (20 µg/ml) was incubated 
with huC1s (0.04 µg/ml; A) or huProC1s (0.4 µg/ml; B) on ice. After a 1-h 
incubation, C4 (5 µg/ml) was added and incubated for 1 h on ice followed 
by EA and 160-fold dilution of C4-deficient GPS. (C) YFV NS1 accelerates 
C4 degradation by proC1s. Purified YFV NS1 (20 µg/ml) was incubated 
with or without huProC1s (0.2 µg/ml) for 1 h on ice followed by the addi-
tion of C4 (2.5 µg/ml). At indicated times after incubation at room tem-
perature, EA and 160-fold dilution of C4-deficient GPS were added and 
hemolysis was determined. The data represent the mean ± SD for three to 
four independent experiments. Asterisks denote hemolysis conditions that 
are statistically different from the cells treated with C1s or proC1s alone 
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(Hortin et al., 1989). As DENV NS1 binds sulfated glycos-
aminoglycans (Avirutnan et al., 2007), it is tempting to spec-
ulate that NS1 binding near the sulfated tyrosine on C4 could 
render it more susceptible to C1s or C1s-like proteases.   
Investigations with mutant NS1 proteins and C4 lacking   
sulfation are planned to directly test this hypothesis.
The presence of C4 protease activity (hamster C1s) in the 
WNV and DENV NS1 preparations initially raised the possi-
bility of a contaminant. Several biochemical experiments, 
however, suggest that the interaction of Flavivirus NS1   
with C1s and C4 is specific: (a) YFV NS1, which does not   
copurify efficiently with hamster C1s, binds C4 but lacks 
cleavage activity. However, addition of YFV NS1 to limiting 
quantities of human proC1s and C1s enhances the cleavage 
rate of C4; (b) WNV, YFV, and DENV NS1 all bind directly 
to human proC1s and C1s by ELISA; (c) WNV NS1 spe-
cifically shifts the size exclusion chromatography profile of   
human proC1s. Although our data suggest that NS1 pro-
motes cleavage of C4 by recruiting and enhancing the   
enzymatic activity of C1s, it remains unclear mechanistically 
how NS1 achieves this. Binding of NS1 to C1s/proC1s may 
cause structural changes that increase the proteolytic activity   
of C1s. Alternatively, oligomeric forms of NS1 could bring   
C4 and C1s together for a sustained interaction that pro-
motes cleavage.
Our data showing that NS1 inhibits the classical and   
lectin pathways of complement activation appears to contrast 
with previous experiments showing that DENV NS1 triggers 
accumulation of C5b-9 complexes in human serum (Avirutnan 
et al., 2006). This discrepancy may be explained by the pres-
ence of natural and neutralizing IgM against NS1 and the   
relative concentrations of NS1 and C4 in serum (compara-
tively low NS1 and high C4) that could attenuate an inhibi-
tory effect on C4 activation. In peripheral tissues where 
the majority of Flavivirus infection occurs, higher local levels 
of NS1 coupled with lower levels of extravascular comple-
ment  and  Ab  concentrations  could  efficiently  inhibit  C4 
function. Flaviviruses, thus, may use NS1 to bind C1s proen-
zyme produced from the same infected cell or neighboring 
cells to inactivate C4 in solution. By forming a complex with 
C1s, NS1 can promote continuous cleavage of C4 to C4b. 
In solution, this nascently generated C4b would have only a 
few microseconds to bind to a target before further hydroly-
sis, as observed with activated C4b. Thus, NS1 targeting of 
C4 could directly limit opsonization and neutralization of   
virions and thereby facilitate local dissemination.
Complement activation has been implicated in the vascu-
lar leakage syndrome of severe DENV infection (Bokisch et al., 
1973; Avirutnan et al., 2006) with C4 consumption occur-
ring in patients with DHF/DSS (Bokisch et al., 1973). The 
NS1 antagonism of complement function could explain   
some of the clinical and pathological findings of severe 
DENV disease. However, severe dengue disease usually 
occurs after secondary DENV infection by a different viral 
serotype. Pre-existing cross-reactive anti-NS1 Abs could 
modulate (enhance or inhibit) the ability of DENV NS1 to   
enhances the cleavage of C4 to C4b in solution, thus decreas-
ing activation by the classical and lectin pathways. The inter-
action between Flavivirus NS1, C1s, and C4 has functional 
consequences, including reduced deposition of C3b and   
C4b on virions and target cells and protection of virus from 
complement-mediated neutralization.
The targeting of C4 in the context of an NS1 interaction 
with proC1s/C1s is a novel evasion strategy to attenuate   
classical and lectin pathway activation. Herpesviruses and 
coronaviruses interfere with CP activation by secreting or 
expressing  decoy  molecules  with  Fc  receptor  function 
(Oleszak et al., 1993; Para et al., 1982), whereas Porphyromonas, 
Streptococcus, and Staphylococcus bacteria degrade IgG and/or 
inhibit IgG interaction with C1q (Björck and Kronvall, 1984; 
Schenkein et al., 1995; von Pawel-Rammingen and Björck, 
2003). Additionally, the Staphylococcus SCIN and Efb proteins 
block CP and alternative pathway C3 and C5 convertases 
(Rooijakkers et al., 2005; Jongerius et al., 2007). Mechanisti-
cally, NS1 promotes cleavage of C4 in solution, which atten-
uates generation of C3b and C5b-9 on targets (e.g., virions or 
virus-infected cells). An analogous cleavage of C3 to C3b-
like proteins by extracellular gelatinase has been described as 
a mechanism of complement evasion by Enterococcus faecalis 
(Park et al., 2008). Our studies do not rule out the possibility 
that NS1 also inhibits complement activation by indepen-
dently preventing C4b attachment to target cells. Unlike 
poxviruses, which express viral virulence factors with struc-
tural and functional similarities to human complement regu-
lators (Rosengard et al., 2002), NS1 itself lacks any apparent 
sequence  homology  to  known  complement  proteins  or   
enzymes. Interestingly, C4 is the only complement protein 
that is sulfated on a tyrosine residue, and this posttranslational 
modification increases the efficiency of C4 cleavage by C1s 
Figure 9.  Soluble NS1 protects DENV from complement attack.  
(A) Neutralization of DENV by GPS. DENV virions were incubated with 
untreated or heat-inactivated (HI) normal GPS for 1 h at 37°C to allow 
complement activation. The samples were then added to BHK-21 mono-
layer, and after agarose overlay, cultured for 5 d. After fixation and stain-
ing of wells, plaques were counted. (B) Soluble DENV NS1 protects DENV 
from complement C4-mediated neutralization. Purified human C4 at the 
indicated concentrations was incubated with soluble DENV NS1 or BSA 
(50 µg/ml) or buffer (PBS) alone for 1 h at room temperature. DENV was 
then added and followed by untreated or HI C4-deficient C4D GPS. Sam-
ples were incubated for 1 h at 37°C before infection of BHK-21 cells, as 
described in A. Data are representative of three independent experiments.JEM VOL. 207, April 12, 2010 
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as two bands (52 kD  chain and 23 kD  chain), whereas proC1s migrates 
as an 80-kD single band (see Fig. 6 E). Under nonreducing conditions, 
C1s and proC1s both migrate as a single 80-kD band. For each preparation 
of proC1s, this type of analysis confirmed the purity of proC1s relative to 
C1s. Furthermore, in functional analyses, 10–100–fold more proC1s than 
C1s was required to cleave an equal quantity of C4.
NS1 and C4/C4b binding ELISA
Maxi-Sorp  microtiter  plates  were  adsorbed  with  purified  C4  or  C4b   
(5 µg/ml in PBS) at 4°C overnight. After five washes with PBS, nonspecific 
binding sites were blocked with 1% heat-inactivated BSA in PBS for 2 h 
at room temperature followed by five washes with PBS. Clarified (200 g, 5 min) 
serum-free  supernatants  from  BHK  or  BHK-DENV2-Rep  cells  were 
added to each well and incubated for 2 h at room temperature. Plates 
were  then  washed  five  times  with  PBS  containing  0.05%  Tween-20   
followed by a 1-h incubation with a mixture of DENV NS1-specific 
mAbs (1A4, 1B2, 1F11, 2G6, and 2E3; 1 µg/ml of each; Puttikhunt   
et al., 2003). After washing, biotinylated goat anti–mouse IgG and horse-
radish peroxidase (HRP)–conjugated streptavidin were added sequen-
tially at room temperature. After six final washes with PBS, signal was 
detected by adding 3,3, 5,5-tetramethylbenzidine substrate. Plates were 
evaluated on a 96-well plate reader (GENois Pro; Tecan Instruments). In 
some experiments, purified NS1 from DENV and WNV (5 µg/ml) was 
used instead of crude supernatants. A mixture of WNV NS1–specific 
mAbs (10NS1, 14NS1, 16NS1, 17NS1, and 22NS1; (Chung et al., 2006b) 
was used to detect WNV NS1.
Immunoprecipitation and Western blot studies
NS1 immunoprecipitation. NS1-containing supernatants were incubated 
with human C4 or C4b at 4°C overnight and then immunoprecipitated with 
anti-NS1 mAb (2G6)–Sepharose. After five washes, bound proteins were 
eluted in SDS reducing sample buffer and separated by 10% SDS-PAGE. 
Western blot was performed using goat anti–human C4 Ab (Quidel) and 
HRP-conjugated anti–goat IgG (GE Healthcare).
C4  immunoprecipitation.  NS1-containing  supernatants  were  incu-
bated with C4 and C4b and immunoprecipitation was performed with 
anti–human C4 Ab-coated beads. After five washes, the samples were 
boiled in SDS sample buffer and separated by 12% SDS-PAGE. Western 
blot  was  performed  using  anti-DENV  NS1  mAb  (1F11)  hybridoma   
supernatant  and  HRP-conjugated  anti–mouse  IgG.  Anti–human  C4   
Ab-coated beads were prepared by adding 5 µg of goat anti–human C4 
polyclonal Ab (Abcam) to 50 µl of TrueBlot anti–goat Ig immunoprecipita-
tion beads (eBioscience).
Erythrocyte hemolysis assay
The assay was performed by a stepwise buildup of complement intermediates 
on EA according to previous work (Krych-Goldberg et al., 1999). EA were 
incubated with C1 (EAC1) for 15 min at 30°C. Before addition to EAC1 cells, 
C4 was preincubated with purified DENV NS1 for 1 h on ice. After a 15-min 
incubation at 30°C, C1- and C4-treated EA (EAC14b) were washed three 
times and incubated with C2 for 4 min at room temperature. C1, C4, and C2 
treated EA (EAC14b2) were washed and incubated with a 20-fold dilution   
of GPS in 40 mM EDTA containing veronal buffered saline (GPS-EDTA) for 
30 min at 37°C. Alternatively, GPS-EDTA was replaced with buffer contain-
ing C3 and each terminal component (C5-C9). In a single-step hemolysis   
assay, EA were incubated with an 80- or 160-fold dilution of C4-deficient GPS 
supplemented with human C4 that was preincubated with DENV NS1 for   
30 min at 37°C. In some experiments, C1 inhibitor (C1-INH; 40 µg/ml) was 
added to before the incubation with EA and C4-deficient GPS. After centrifu-
gation, erythrocyte lysis was assayed in the supernatant by spectrophotometry 
at 414 nm.
For preclearing experiments DENV NS1 was incubated with anti-NS1 
(2G6) or anti-E (4G2; negative control) Sepharose beads for 4 h at 4°C. The 
attenuate complement activation during secondary infec-
tion. Such an interaction at endothelial or serosal sites could 
trigger dysfunctional complement responses by NS1-Ab   
immune complexes that promote fluid extravasation into 
pleural and peritoneal spaces, a characteristic of DHF/DSS 
(Nimmannitya, 1987). Alternatively, antagonism of C4 func-
tion by NS1 may have a more important role in primary   
Flavivirus infection by enhancing the infectivity of virus in 
serum or tissues, which otherwise can be neutralized by com-
plement. An improved understanding of the novel immune 
evasion mechanisms of Flavivirus NS1 will likely foster   
insight  into  the  host-pathogen  interactions  that  modulate   
disease severity.
In summary, our results point to formation of a complex 
of soluble NS1 with human C1s and C4. This complex   
promotes cleavage by C1s of C4 to C4b and thereby limits 
the supply of native C4 to participate in complement activa-
tion at the infectious site. NS1 derived from at least three 
clinically important Flaviviruses, DENV, WNV, and YFV, 
possesses this immune evasion activity for the human com-
plement system.
MATERIALS AND METHODS
Purified Flavivirus NS1 and complement proteins
DENV  NS1  was  produced  and  isolated  as  previously  described  from 
DENV2-infected mammalian cells and BHK-DENV2-Rep cells (Avirutnan 
et al., 2006, 2007). WNV and YFV NS1 were isolated from supernatants of 
BHK-WNV-Rep and BHK-YFV-Rep cells as previously described (Chung 
et al., 2006a; Patkar and Kuhn, 2008) or BHK cells infected with recombi-
nant Sindbis viruses encoding Flavivirus NS1. WNV and YFV NS1 were 
expressed using the double subgenomic Sindbis virus 39 E2H55K50 (39HK; 
Ryman et al., 2007). In brief, the NS1 gene of WNV and YFV including a 
24-amino acid signal sequence corresponding to the C-terminus of the E 
protein  was  amplified  from  infected  Vero  cells  by  RT-PCR  using  the   
following oligonucleotide primers (WNV NS1 forward 5-GGGCGGCC-
GCACCATGGATAGGTCCATAGCTCTCACGTTT-3; WNV NS1   
reverse  5-CTGCGGCCGCTAAGCATTCACTTGTGACTGCAC-3; 
YFV NS1 forward 5-GCGGCCGCACCATGGACATGACAATGTCC-
ATGAGCA-3;  YFV  NS1  reverse  5-TCAAGCTGTAACCCAGGA-
GCGCACCAG-3). WNV and YFV NS1 were subcloned into 39HK after 
digestion with NotI and PmeI restriction enzymes. After sequencing,   
recombinant 39HK expressing WNV or YFV NS1 (39HK WNV NS1 or 
39HK YFV NS1) was produced by SP6 DNA-dependent RNA polymerase 
in vitro transcription. DNA templates linearized with XhoI were transcribed 
in vitro by SP6 RNA polymerase using mMESSAGE mMACHINE kit 
(Ambion)  following  the  manufacturer’s  instruction.  In  vitro–transcribed 
RNA was electroporated into BHK cells with 3 consecutive electrical pulses 
of 850 V at 25 µF and  Ω using the Gene Pulser Xcell (Bio-Rad Laborato-
ries) and double subgenomic infectious viruses were harvested 2 d later. 
WNV or YFV NS1 was harvested from supernatants of BHK cells infected 
with 39HK WNV NS1 or 39HK YFV NS1 at a multiplicity of infection 
(MOI) of 1 in serum-free DME at 36 h. Infectious recombinant Sindbis   
virus was inactivated by -propiolactone treatment at 37°C overnight or 
NP-40 (0.05% [vol/vol] final concentration) before NS1 purification using 
a Flavivirus cross-reactive anti-NS1 (9NS1; Chung et al., 2006b) Sepharose 
4B column. A two-step purification of Flavivirus NS1 was performed as   
described previously (Avirutnan et al., 2007) using ion exchange or size   
exclusion chromatography. 
All purified human complement proteins were purchased commercially 
(Complement  Technologies)  unless  otherwise  stated.  To  differentiate   
between C1s and proC1s, SDS-PAGE and Western blot analysis were   
performed: under reducing (5% -mercaptoethanol) conditions, C1s appears 804 Flavivirus NS1 inhibits C4 function | Avirutnan et al.
Direct interaction of NS1 and C1s
Size exclusion chromatography. Purified WNV NS1 (50 µg) or human 
proC1s (15 µg) or Fab fragment of murine mAb to WNV E protein (E9-Fab; 
15 µg) in PBS was fractionated in a Superose 6 column (GE Healthcare) at a 
rate of 0.5 ml/min. 15 fractions (1 ml each) were collected and concentrated 
10-fold by 0.5 ml centrifugal filter devices (Amicon Ultra; Millipore) before 
SDS-PAGE and Western blot with biotinylated anti-WNV NS1 mAb 3NS1 
(0.5 µg/ml; Chung et al., 2006b) followed by HRP-conjugated streptavidin 
(1:5,000; Vector Laboratories) or goat antiserum to human C1s (1:5,000; 
Quidel) followed by donkey anti–goat IgG (1:5,000; Sigma-Aldrich), and 
HRP-conjugated goat anti–mouse IgG (Sigma-Aldrich; 1:5,000). In some 
experiments, WNV NS1 was preincubated with proC1s or E9-Fab for 1 h 
on ice before loading onto a size exclusion column.
ELISA. Microtiter plates were coated with purified human C1s or proC1s 
or BSA (10 µg/ml in PBS). After five washes with PBS, nonspecific binding 
sites were blocked with 2% heat inactivated BSA in PBS for 2 h at room 
temperature followed by five washes with PBS. Purified WNV, DENV,   
or YFV NS1 at various concentrations was added to each well and incubated 
for 2 h at room temperature. Bound WNV or DENV NS1 was detected   
as described above. A 1:700 dilution of ascites fluid containing the YFV   
specific anti-NS1 mAb 4E3 (Schlesinger et al., 1985) was used to detect   
YFV NS1.
Serum neutralization of DENV
Neutralization of DENV by C4-deficient GPS, with and without reconsti-
tution with human C4 and in the presence or absence of DENV NS1 pro-
tein,  was  tested  in  a  plaque  assay  using  BHK-21  cells.  Human  C4  was 
incubated with soluble DENV NS1 or BSA (final protein concentration of 
50 µg/ml, diluted in gelatin veronal buffer with Mg2+ and Ca2+ [GVB2+]; 
CompTech) for 1 h at room temperature. DENV2 strain 16681 (2 × 102 
PFU) was then added to the mixture of NS1-C4 or BSA-C4, followed by 
C4-deficient GPS, either untreated or heat inactivated (56°C for 30 min) 
diluted in GVB2+ buffer to a final serum concentration of 10%. Samples were 
incubated  for  1  h  at  37°C  and  then  added  to  BHK-21  monolayers  in   
duplicate. Infection of BHK-21 cells occurred for 90 min at 37°C; after that 
the cells were washed extensively with DMEM, overlaid with 1% agarose in 
Minimal Essential Media supplemented with 2% FBS, and cultured for five 
days  at  37°C.  After  formaldehyde  fixation  (10%  vol/vol)  and  staining   
of wells with a 1% (wt/vol) crystal violet solution in 20% ethanol, plaques 
were counted.
Statistical analysis
Datasets were compared by a two-tailed, unpaired Student’s t test. Multiple 
comparisons were performed using an analysis of variance test. Statistical   
significance was achieved when P values were <0.05.
Online supplemental material
Using preclearance experiments, Fig. S1 shows that the inhibitory activity 
against C4 in a hemolysis assay is NS1-dependent. Fig. S2 demonstrates that 
NS1 lacks the ability to regulate C3 convertase or C3 and C5 decay acceler-
ating activity. Fig. S3 shows that NS1 lacks cofactor activity for factor I to 
degrade C4b. Fig. S4 establishes that the ability of NS1 to promote C4 deg-
radation is specific as proteolysis of C3 was not observed. Fig. S5 provides an 
analysis of WNV NS1 by SDS-PAGE and Western blot after purification by 
immunoaffinity and ion-exchange chromatography. Fig. S6 presents an anal-
ysis of WNV NS1 by SDS-PAGE and Western blot after purification by size 
exclusion chromatography. Online supplemental material is available at http:// 
www.jem.org/cgi/content/full/jem.20092545/DC1.
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quantity of DENV NS1 after preclearing was analyzed by Western blot. The 
precleared solutions also were subjected to a single-step hemolysis assay.
The assay for decay-accelerating activity was performed essentially as 
previously described (Krych-Goldberg et al., 2005). To prepare the CP C3 
convertase, EAC14b were incubated for 4 min at room temperature with 
C2; for the CP C5 convertase, cells were incubated under the same condi-
tions with C2 and C3. EAC14b2a or EAC14b2a3b were incubated with 
purified DENV NS1, sCR1, or C4BP for 10 min at 30°C. Subsequently, 
GPS-EDTA was added and hemolysis was determined.
To test for the activity of Flavivirus NS1 to enhance C1s/proC1s   
activity, purified WNV, DENV, and YFV NS1 (20 µg/ml) was incubated 
with C1s (0.04 µg/ml) or proC1s (0.4 µg/ml) on ice. After a 1-h preincu-
bation,  C4  (4µg/ml)  was  added  to  the  NS1-C1s/proC1s  mixture  and   
incubated for 1 h on ice. 50 µl of EA (8 × 106 cells) and 500 µl of a 160-
fold dilution of C4-deficient GPS were added and incubated for 30 min at 
37°C, and then hemolysis was determined. In some experiments, purified 
YFV NS1 (20 µg/ml) was incubated with proC1s (0.2 µg/ml) for 1 h on 
ice. Purified human C4 (2.5 µg/ml) was then added to NS1-proC1s mix-
ture and incubated for 0, 5, 15, 30, 45, and 60 min at room temperature 
followed by the addition of EA- and C4-deficient GPS as described in the 
first paragraph of this section.
C4b cofactor activity assay
Purified soluble complement receptor-1 (sCR1) was a gift (H. Marsh, 
Avant Immunotherapeutics, Inc., Needham, MA). Recombinant MCP 
was generated as previously described (Liszewski et al., 2006). C4b was in-
cubated with purified DENV NS1 or WNV NS1 or BSA for 1 h at 4°C. 
Subsequently, factor I, with or without a cofactor (C4BP or sCR1 or 
MCP), was added to the C4b-NS1 solution. After a 2-h incubation at 
37°C, reducing sample buffer was added, and the fragments of C4b were 
separated on 10% SDS-PAGE. Western blot was performed using an anti-
C4d mAb (Quidel) and a HRP-conjugated anti–mouse IgG.
C3b and C4b deposition on erythrocyte cell surface
EAC1 was prepared as described above. Human C4 was incubated with 
purified DENV NS1 or C4BP for 1 h on ice before adding EAC1. After a 
15-min incubation at 30°C, EAC14b were sequentially incubated with C2 
and C3 as described above. The deposition of C3b and C4b was deter-
mined by staining with anti-C3c and anti-C4c mAbs, respectively. After 
three washes, cells were incubated with Alexa Fluor 647–conjugated anti–
mouse IgG and analyzed by flow cytometry.
Complement activation on the surface of CHO cells
This  assay  was  modified  from  the  published  protocols  (Barilla-LaBarca   
et al., 2002; Liszewski et al., 2008) and performed in 96-well plates seeded 
with 106 cells/well. CHO cells were sensitized with 50 µg/ml rabbit anti-
CHO surface antigen IgG at 4°C on a shaker (600 rpm). After a 30 min 
incubation, the cells were incubated with the mixture of DENV NS1   
or BSA (25 µg/ml) and purified human CP complement component C1 
(2.5 µg/ml), C2 (2 µg/ml), C3 (10 µg/ml), and C4 (6.67 µg/ml) in   
GVB2+ buffer for 45 min at 4°C on a shaker. Deposition of C3d and C4d 
was detected by flow cytometry as described above with a murine mAb to 
human C3d or C4d (10 µg/ml; Quidel).
Assessment of C4 cleavage
Western blot. C4 was incubated with NS1 on ice for 1 h. In some exper-
iments, purified C1qrs or C1s was added to an NS1-C4 mixture. At vari-
ous  time  points,  reducing  sample  buffer  was  added,  and  samples  were 
separated by 10% SDS-PAGE. Western blot was performed using goat 
anti–human C4 Ab as described above.
C4a ELISA. Purified C4 was incubated with purified NS1 in the presence 
or absence of C1-INH (40 µg/ml) on ice for 1 h. After a second 1 h incu-
bation at 37°C, C4a was measured with the BD OptEIA Human C4a 
ELISA kit (BD).JEM VOL. 207, April 12, 2010 
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